4D Molecular Therapeutics Inc Forecast, price target & analysts
4D Molecular Therapeutics Inc Target price 2025 - Analyst rating & recommendation
4D Molecular Therapeutics Inc Classifications & Recommendation:
4D Molecular Therapeutics Inc Price Target
| Target Price | $32.10 |
| Price | $3.85 |
| Potential |
733.77%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target 4D Molecular Therapeutics Inc 2026 .
The average 4D Molecular Therapeutics Inc target price is $32.10.
This is
733.77%
register free of charge
$45.00
1,068.83%
register free of charge
$10.00
159.74%
register free of charge
|
|
| A rating was issued by 12 analysts: 9 Analysts recommend 4D Molecular Therapeutics Inc to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the 4D Molecular Therapeutics Inc stock has an average upside potential 2026 of
733.77%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.04 | 3.87 |
| 99.81% | 9,582.25% | |
| EBITDA Margin | -457,975.00% | -6,083.22% |
| 87,229.67% | 98.66% | |
| Net Margin | -345,084.00% | -4,066.41% |
| 59,731.01% | 98.82% |
10 Analysts have issued a sales forecast 4D Molecular Therapeutics Inc 2025 . The average 4D Molecular Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an 4D Molecular Therapeutics Inc EBITDA forecast 2025. The average 4D Molecular Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 4D Molecular Therapeutics Inc Analysts have issued a net profit forecast 2025. The average 4D Molecular Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.98 | -3.40 |
| 15.50% | 14.09% | |
| P/E | negative | |
| EV/Sales | negative |
4 Analysts have issued a 4D Molecular Therapeutics Inc forecast for earnings per share. The average 4D Molecular Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
4D Molecular Therapeutics Inc...
Current 4D Molecular Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 09 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
